Antibody therapy for Ebola: Is the tide turning around?

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 4, 2014, Pages 964-967

  Qiu, Xiangguo ^a   Kobinger, Gary P ^a,b,c  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antibody therapy; Ebola virus; Filovirus; Infectious disease; mAb cocktail; Nonhuman primates; Passive immunization

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

BIOSAFETY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EPIDEMIC; FILOVIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; NONHUMAN; NOTE; PASSIVE IMMUNIZATION; VIRUS NEUTRALIZATION; VIRUS VIRULENCE; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; HEMORRHAGIC FEVER, EBOLA; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84899811930     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27813     Document Type: Note

References (35)

1. Roux E, Yersin A. Contribution à l'étude de la diphtérie. Ann Inst Pasteur (Paris) 1888; 2:629-61
2. Behring E, Kitasato S. Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Deutsche Medizinsche Wochenschrift 1890; 16:1113e4.
3. Simon CE. An introduction to the study of infection and immunity, including chapters on serum therapy, vaccine therapy, chemotherapy and serum diagnosis for students and practitioners. Philadelphia, Pa: Lea and Febiger, 1912.
4. Reimann HA. The pneumonias. St. Louis, Mo.: W. H. Green, 1971.
5. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7; PMID:1172191; http://dx.doi.org/10.1038/256495a0
6. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008; 8:473-80; PMID:18469827; http://dx.doi.org/10. 1038/nrc2394
7. Handbook of Therapeutic Antibodies. Wiley, Weinhem, 2007.
8. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23:1117-25; PMID:16151405; http://dx.doi.org/10.1038/nbt1135
9. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073-8; PMID:16151394; http://dx.doi.org/10.1038/nbt0905-1073
10. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003; 9:269-77; PMID:12612576; http://dx.doi.org/10.1038/nm0303-269
11. Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013; 5:1-4; PMID:23254906; http://dx.doi.org/10.4161/mabs.22976
12. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008; 317:103-23; PMID:17990791; http://dx.doi.org/10.1007/ 978-3-540-72146-8-4
13. Gronvall GK, Rambhia KJ, Adalja AA, Cicero A, Inglesby T, Kadlec R. Next-generation monoclonal antibodies: challenges and opportunities. Center for Biosecurity of UPMC. 2013 Feb. 60 p. Contract No.: HDTRA1-11-D-0004. Supported by DTRA Chem Bio Directorate and TASC, Inc.
14. Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov 2006; 5:191-5; PMID:16518372; http://dx.doi.org/10.1038/nrd1987
15. Hughes JM. Preserving the lifesaving power of antimicrobial agents. JAMA 2011; 305:1027-8; PMID:21343545; http://dx.doi.org/10.1001/jama.2011.279
16. Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Caì Y, Chandran K, Davey RA, et al. Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol 2013; 158:1425-32; PMID:23358612; http://dx.doi.org/10.1007/s00705-012-1594-2
17. Negredo A, Palacios G, Vázquez-Morón S, González F, Dopazo H, Molero F, Juste J, Quetglas J, Savji N, de la Cruz Martínez M, et al. Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog 2011; 7:e1002304; PMID:22039362; http://dx.doi.org/10.1371/journal.ppat.1002304
18. CDC. Known cases and outbreaks of Ebola hemorrhagic fever, in chronological order. 2013. Available from: http://www.cdc.gov/ncidod/dvrd/spb/ mnpages/dispages/ebola/ebolatable.htm
19. Borchert M, Mutyaba I, Van Kerkhove MD, Lutwama J, Luwaga H, Bisoborwa G, Turyagaruka J, Pirard P, Ndayimirije N, Roddy P, et al. Ebola haemorrhagic fever outbreak in Masindi District, Uganda: outbreak description and lessons learned. BMC Infect Dis 2011; 11:357; PMID:22204600; http://dx.doi.org/10.1186/ 1471-2334-11-357
20. Qiu X, Wong G, Audet J, Kobinger GP. Therapeutic monoclonal antibodies for Ebola hemorrhagic fever. New York, NY: Nova Science Publishers, 2014 (in press).
21. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ; International Scientific and Technical Committee. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999; 179(Suppl 1):S18-23; PMID:9988160; http://dx.doi.org/10.1086/514298
22. Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, Huggins JW, Schmidt JJ, LeDuc JW, Peters CJ. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996; 11:135-40; PMID:8800795
23. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007; 196(Suppl 2):S400-3; PMID:17940976; http://dx.doi.org/10.1086/ 520587
24. Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, Parren PW, Burton DR. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007; 3:e9; PMID:17238286; http://dx.doi.org/10.1371/journal.ppat.0030009
25. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012; 109:5034-9; PMID:22411795; http://dx.doi.org/10.1073/pnas.1200409109
26. Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, Matsuyama Y, Igarashi M, Nakayama E, Kuroda M, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012; 7:e36192; PMID:22558378; http://dx.doi.org/10. 1371/journal.pone.0036192
27. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012; 4:38ra81; PMID:22700957; http://dx.doi.org/10.1126/scitranslmed.3003876
28. Olinger GG Jr., Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 2012; 109:18030-5; PMID:23071322; http://dx.doi.org/10.1073/pnas.1213709109
29. Wong G, Richardson JS, Pillet S, Patel A, Qiu X, Alimonti J, Hogan J, Zhang Y, Takada A, Feldmann H, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012; 4:ra146; PMID:23115355; http://dx.doi.org/10.1126/scitranslmed. 3004582
30. Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 2013; 110:1893-8; PMID:23319647; http://dx.doi.org/10.1073/pnas.1209591110
31. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M Jr., Lifson JD, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-80; PMID:24172896
32. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-8; PMID:24172905
33. Pettitt J, Zeitlin L, Kim H, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 2013; 5:ra113; PMID:23966302; http://dx.doi.org/10.1126/scitranslmed. 3006608
34. Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J, Alimonti JB, Kobinger GP. mAbs and Ad-Vectored IFN-α therapy rescue ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013; 5:ra143; PMID:24132638; http://dx.doi.org/10.1126/ scitranslmed.3006605
35. Summary E. Proceedings of a State-of-the Art Workshop on Medical Countermeasures Potentially Available for Human Use Following an Accidental Laboratory Exposure to BSL-4 Agents. National Interagency Confederation for Biological Research (NICBR), 2013.